id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0610-0012,FDA,FDA-2008-D-0610,Guidance For Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic,Other,Guidance,2012-02-24T05:00:00Z,2012,2,2012-02-24T05:00:00Z,,2012-02-24T15:11:42Z,,0,0,0900006480fc051a
FDA-2008-D-0610-0011,FDA,FDA-2008-D-0610,Guidance For Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic; Availability,Notice,Notice of Availability,2012-02-24T05:00:00Z,2012,2,2012-02-24T05:00:00Z,,2012-02-24T14:57:14Z,2012-04288,0,0,0900006480fc01ae